Kymab
Cambridge
About Kymab
Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics with a focus on immune-mediated diseases and immuno-oncology using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab’s IntelliSelect Transgenic platforms contain a full diversity of human antibodies, making them the most comprehensive antibody platforms available. The company was founded in 2010 and is based in Cambridge, the United Kingdom.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $229.4M
- Funding stage: M&A
- Last round: Grant (Jan 2017)
- Website: kymab.com
- Phone: 44 1223 833301
Industries & Categories
Biopharma, Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/kymab-137736 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.